Whole genome sequencing of glioblastoma multiforme identifies multiple structural variations involved in EGFR activation

Mutagenesis

Volumn 29, Issue 5, 2014, Pages 341-350

  Furgason, John M ^a   Li, Wenge ^b   Milholland, Brandon ^b   Cross, Emily ^a   Li, Yaqin ^a   McPherson, Christopher M ^a,c   Warnick, Ronald E ^a,c   Rixe, Olivier ^d   Stambrook, Peter J ^a   Vijg, Jan ^b   Bahassi, El Mustapha ^a,c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; MICRORNA;

AMINO ACID SEQUENCE; BRAIN TUMOR; COPY NUMBER VARIATION; DNA SEQUENCE; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION REGULATION; GENE LIBRARY; GENETICS; GLIOBLASTOMA; HIGH THROUGHPUT SEQUENCING; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MOLECULAR GENETICS; PROCEDURES;

AMINO ACID SEQUENCE; BRAIN NEOPLASMS; DNA COPY NUMBER VARIATIONS; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE LIBRARY; GLIOBLASTOMA; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOHISTOCHEMISTRY; MICRORNAS; MOLECULAR SEQUENCE DATA; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE ANALYSIS, DNA;

EID: 84906812646     PISSN: 02678357     EISSN: 14643804     Source Type: Journal    
DOI: 10.1093/mutage/geu026     Document Type: Article

References (58)

1. Ohgaki, H. and Kleihues, P. (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J. Neuropathol. Exp. Neurol., 64, 479-489.
2. Stupp, R., Mason, W. P., van den Bent, M. J., et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med., 352, 987-996.
3. Phillips, H. S., Kharbanda, S., Chen, R., et al. (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell, 9, 157-173.
4. Liang, Y., Diehn, M., Watson, N., et al. (2005) Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc. Natl. Acad. Sci. U. S. A., 102, 5814-5819.
5. Brennan, C., Momota, H., Hambardzumyan, D., Ozawa, T., Tandon, A., Pedraza, A. and Holland, E. (2009) Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One, 4, e7752.
6. Gravendeel, L. A. M., Kouwenhoven, M. C. M., Gevaert, O., et al. (2009) Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res., 69, 9065-9072.
7. Verhaak, R. G. W., Hoadley, K. A., Purdom, E., et al. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 17, 98-110.
8. Vitucci, M., Hayes, D. N. and Miller, C. R. (2011) Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy. Br. J. Cancer, 104, 545-553.
9. Cheng, W. Y., Kandel, J. J., Yamashiro, D. J., Canoll, P. and Anastassiou, D. (2012) A multi-cancer mesenchymal transition gene expression signature is associated with prolonged time to recurrence in glioblastoma. PLoS One, 7, e34705.
10. Biernat, W., Kleihues, P., Yonekawa, Y. and Ohgaki, H. (1997) Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J. Neuropathol. Exp. Neurol., 56, 180-185.
11. Brennan, C. W., Verhaak, R. G. W., McKenna, A., et al. (2013) The somatic genomic landscape of glioblastoma. Cell 155, 462-477.
12. Frattini, V., Trifonov, V., Chan, J. M., et al. (2013) The integrated landscape of driver genomic alterations in glioblastoma. Nat. Genet., 45, 1141-1149.
13. Zhang, H., Berezov, A., Wang, Q., Zhang, G., Drebin, J., Murali, R. and Greene, M. I. (2007) ErbB receptors: from oncogenes to targeted cancer therapies. J. Clin. Invest., 117, 2051-2058.
14. Wong, A. J., Bigner, S. H., Bigner, D. D., Kinzler, K. W., Hamilton, S. R. and Vogelstein, B. (1987) Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc. Natl. Acad. Sci. U. S. A., 84, 6899-6903.
15. Sauter, G., Maeda, T., Waldman, F. M., Davis, R. L. and Feuerstein, B. G. (1996) Patterns of epidermal growth factor receptor amplification in malignant gliomas. Am. J. Pathol., 148, 1047-1053.
16. Atlas, T. C. G. (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 455, 1061-1068.
17. Smith, J. S., Tachibana, I., Passe, S. M., et al. (2001) PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J. Natl. Cancer Inst., 93, 1246-1256.
18. Shinojima, N., Tada, K., Shiraishi, S., et al. (2003) Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res., 63, 6962-6970.
19. Hobbs, J., Nikiforova, M. N., Fardo, D. W., Bortoluzzi, S., Cieply, K., Hamilton, R. L. and Horbinski, C. (2012) Paradoxical relationship between the degree of EGFR amplification and outcome in glioblastomas. Am. J. Surg. Pathol., 36, 1186-1193.
20. Hurtt, M. R., Moossy, J., Donovan-Peluso, M. and Locker, J. (1992) Amplification of epidermal growth factor receptor gene in gliomas: histopathology and prognosis. J. Neuropathol. Exp. Neurol., 51, 84-90.
21. Simmons, M. L., Lamborn, K. R., Takahashi, M., et al. (2001) Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res., 61, 1122-1128.
22. Ruano, Y., Ribalta, T., de Lope, A. R., Campos-Martín, Y., Fiaño, C., Pérez- Magán, E., Hernández-Moneo, J. L., Mollejo, M. and Meléndez, B. (2009) Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration. Am. J. Clin. Pathol., 131, 257-263.
23. Srividya, M. R., Thota, B., Arivazhagan, A., Thennarasu, K., Balasubramaniam, A., Chandramouli, B. A., Hegde, A. S. and Santosh, V. (2010) Age-dependent prognostic effects of EGFR/p53 alterations in glioblastoma: study on a prospective cohort of 140 uniformly treated adult patients. J. Clin. Pathol., 63, 687-691.
24. Huncharek, M. and Kupelnick, B. (2000) Epidermal growth factor receptor gene amplification as a prognostic marker in glioblastoma multiforme: results of a meta-analysis. Oncol. Res., 12, 107-112.
25. Heimberger, A. B., Hlatky, R., Suki, D., Yang, D., Weinberg, J., Gilbert, M., Sawaya, R. and Aldape, K. (2005) Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin. Cancer Res., 11, 1462-1466.
26. Carico, C., Nuño, M., Mukherjee, D., et al. (2012) Loss of PTEN Is Not Associated with Poor Survival in Newly Diagnosed Glioblastoma Patients of the Temozolomide Era. PLoS One, 7, e33684.
27. Maa, M. C., Leu, T. H., McCarley, D. J., Schatzman, R. C. and Parsons, S. J. (1995) Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers. Proc. Natl. Acad. Sci. U. S. A., 92, 6981-6985.
28. Lo, H. W., Cao, X., Zhu, H. and Ali-Osman, F. (2008) Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin. Cancer Res., 14, 6042-6054.
29. Schmidt, E. E., Ichimura, K., Reifenberger, G. and Collins, V. P. (1994) CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res., 54, 6321-6324.
30. Jen, J., Harper, J. W., Bigner, S. H., Bigner, D. D., Papadopoulos, N., Markowitz, S., Willson, J. K., Kinzler, K. W. and Vogelstein, B. (1994) Deletion of p16 and p15 genes in brain tumors. Cancer Res., 54, 6353-6358.
31. Li, L., Dutra, A., Pak, E., Labrie, J. E., 3rd, Gerstein, R. M., Pandolfi, P. P., Recht, L. D. and Ross, A. H. (2009) EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors. Neuro. Oncol., 11, 9-21.
32. McEllin, B., Camacho, C. V., Mukherjee, B., Hahm, B., Tomimatsu, N., Bachoo, R. M. and Burma, S. (2010) PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res., 70, 5457-5464.
33. Nakamura, M., Watanabe, T., Klangby, U., Asker, C., Wiman, K., Yonekawa, Y., Kleihues, P. and Ohgaki, H. (2001) p14ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol., 11, 159-168.
34. Gundry, M., Li, W., Maqbool, S. B. and Vijg, J. (2012) Direct, genomewide assessment of DNA mutations in single cells. Nucleic Acids Res., 40, 2032-2040.
35. Quail, M. A., Swerdlow, H. and Turner, D. J. (2009) Improved protocols for the illumina genome analyzer sequencing system. Curr. Protoc. Hum. Genet., 18, Unit 18.2.
36. Langmead, B., Trapnell, C., Pop, M. and Salzberg, S. L. (2009) Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol., 10, R25.
37. Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G. and Durbin, R. (2009) The Sequence Alignment/Map format and SAMtools. Bioinformatics, 25, 2078-2079.
38. DePristo, M. A., Banks, E., Poplin, R., et al. (2011) A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet., 43, 491-498.
39. Boeva, V., Popova, T., Bleakley, K., Chiche, P., Cappo, J., Schleiermacher, G., Janoueix-Lerosey, I., Delattre, O. and Barillot, E. (2012) Control- FREEC: a tool for assessing copy number and allelic content using nextgeneration sequencing data. Bioinformatics, 28, 423-425.
40. Chen, K., Wallis, J. W., McLellan, M. D., et al. (2009) BreakDancer: an algorithm for high-resolution mapping of genomic structural variation. Nat. Methods, 6, 677-681.
41. Robinson, J. and Winckler, W. (2011) Integrative genomics viewer. Nature, 29, 24-26.
42. Krzywinski, M., Schein, J., Birol, I., Connors, J., Gascoyne, R., Horsman, D., Jones, S. J. and Marra, M. A. (2009) Circos: an information aesthetic for comparative genomics. Genome Res., 19, 1639-1645.
43. Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P. and Mak, T. W. (1998) Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell, 95, 29-39.
44. Sos, M. L., Koker, M., Weir, B. A., et al. (2009) PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res., 69, 3256-3261.
45. Yin, D., Ogawa, S., Kawamata, N., Leiter, A., Ham, M., Li, D., Doan, N. B., Said, J. W., Black, K. L. and Phillip Koeffler, H. (2013) miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme. Oncogene, 32, 1155-1163.
46. Zhang, X., Pickin, K. A., Bose, R., Jura, N., Cole, P. A. and Kuriyan, J. (2007) Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature, 450, 741-744.
47. Zhang, Y.-W., Staal, B., Su, Y., Swiatek, P., Zhao, P., Cao, B., Resau, J., Sigler, R., Bronson, R. and Vande Woude, G. F. (2007) Evidence that MIG-6 is a tumor-suppressor gene. Oncogene, 26, 269-276.
48. Fiorentino, L., Pertica, C., Fiorini, M., Talora, C., Crescenzi, M., Castellani, L., Alemà, S., Benedetti, P. and Segatto, O. (2000) Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domain. Mol. Cell. Biol., 20, 7735-7750.
49. Duncan, C. G., Killela, P. J., Payne, C. A., et al. (2010) Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes. Oncotarget, 1, 265-277.
50. Xu, D., Makkinje, A. and Kyriakis, J. M. (2005) Gene 33 is an endogenous inhibitor of epidermal growth factor (EGF) receptor signaling and mediates dexamethasone-induced suppression of EGF function. J. Biol. Chem., 280, 2924-2933.
51. Anastasi, S., Fiorentino, L., Fiorini, M., Fraioli, R., Sala, G., Castellani, L., Alemà, S., Alimandi, M. and Segatto, O. (2003) Feedback inhibition by RALT controls signal output by the ErbB network. Oncogene, 22, 4221-4234.
52. Frosi, Y., Anastasi, S., Ballarò, C., Varsano, G., Castellani, L., Maspero, E., Polo, S., Alemà, S. and Segatto, O. (2010) A two-tiered mechanism of EGFR inhibition by RALT/MIG6 via kinase suppression and receptor degradation. J. Cell Biol., 189, 557-571.
53. Frederick, L., Eley, G., Wang, X. Y. and James, C. D. (2000) Analysis of genomic rearrangements associated with EGRFvIII expression suggests involvement of Alu repeat elements. Neuro. Oncol., 2, 159-163.
54. Zhu, H., Acquaviva, J., Ramachandran, P., et al. (2009) Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc. Natl. Acad. Sci. U. S. A., 106, 2712-2716.
55. Grandal, M. V., Zandi, R., Pedersen, M. W., Willumsen, B. M., van Deurs, B. and Poulsen, H. S. (2007) EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes. Carcinogenesis, 28, 1408-1417.
56. Waterman, H., Katz, M., Rubin, C., Shtiegman, K., Lavi, S., Elson, A., Jovin, T. and Yarden, Y. (2002) A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling. EMBO J., 21, 303-313.
57. Karpel-Massler, G., Andrew Westhoff, M., Richard, E. K., Rainer Wirtz, C. and Halatsch, M.-E. Erlotinib in Glioblastoma - Lost in Translation? Anti-Cancer Agents in Medicinal Chemistry, 11, 748-755.
58. Chang, T.-C., Wentzel, E. A., Kent, O. A., et al. (2007) Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell, 26, 745-752.